Awakn Life Sciences Corporation (PK) (AWKNF) 시세

Huge bids rolling in

Ready for a big day!


$AWKN $AWKNF

Good Morning $AWKNF

Analysts forecasting 1400% upside??

https://www.tipranks.com/stocks/awknf/forecast

I saw 100k on the bid yesterday .. $AWKNF $AWKN

Nice and green ! $AWKNF $AWKN

That would be hugggggeeee!! WOW! Some nice activity here today, who's buying?

$AWKN $AWKNF has applied for several grants, one of which the company expects to receive a response on by end of Q2, and if successful, would cover a substantial amount of the cost of Phase III clinical trial

Awakn Life Sciences is a biotechnology company focused on the research, development, and delivery of psychedelic medicines for the treatment of mental health conditions. Awakn is creating a paradigm shift in psychiatry by integrating psychedelic medicine into mainstream mental healthcare with a strategic focus on the treatment of Addiction, Anxiety, Depression and PTSD across three business lines of Research, Clinics and Platforms. For more information, please visit awaknlifesciences.com
OUR STRATEGY
We are a biotechnology company focused on the research, development, and delivery of psychedelic medicines for the treatment of mental health conditions in the UK, EU, and North America with a dual strategic focus of create and commercialising psychedelic IP focused on treating addiction and treat mental health through a chain of owned and operated medical psychedelic clinics in the UK and EU.
KEY MEMBERS OF OUR TEAM
Chair of Scientific Advisory Board: Prof. David Nutt DM, FRCP, FRCPsych, FSB, FMEDSCI
The Chairman of the Awakn Scientific Advisory Board has been at the cutting edge of drug research since 1972. He established the Drug Science charity, and in 2008 was appointed Chair of the Advisory Council on the Misuse of Drugs, which reported to the UK’s Conservative government. His remarkable career is documented in his bestselling book, Nutt Uncut.


Chief Medical Officer: Dr. Ben Sessa MBBS (MD), MRCPsych
Our Chief Medical Officer has been at the cutting edge of psychedelic therapy research for over a decade, along the way authoring three books including 2012’s The Psychedelic Renaissance, which is considered a key work on the subject. Ben was one of the leads on the groundbreaking Bristol-Imperial MDMA-for-Alcoholism Study (BIMA).
Chief Science Officer: Dr. Sean McNulty BSc, D. Phil
Shaun is an experienced biotechnology executive with over 20 years of experience in drug development with Pfizer, GSK, Syntaxin, ImmBio, Biosceptre and Inflection Biosciences.
?

Shaun holds a D. Phil from the University of York and researched CNS biology and signalling at the University of Cambridge, UK.
Chief Science Officer: Dr. Sean McNulty BSc, D. Phil
Shaun is an experienced biotechnology executive with over 20 years of experience in drug development with Pfizer, GSK, Syntaxin, ImmBio, Biosceptre and Inflection Biosciences.
?
Shaun holds a D. Phil from the University of York and researched CNS biology and signalling at the University of Cambridge, UK.


Lead Psychologist: Dr. Laurie Higbed BSc. (Hons), ClinPsyD
Laurie is an experienced clinical psychologist. Laurie has worked as a lead therapist on clinical trials using MDMA and psilocybin-assisted psychotherapy and has a special interest in working with complex trauma, addictions and the use of psychedelic therapy to treat a range of mental health difficulties.
Ketamine Alcohol Use Disorder Practice Lead: Prof. Celia Morgan Ph. D, BSc, Dip SciComm
Celia is a Professor of Psychopharmacology at the University of Exeter, one of Europe’s leading ketamine researchers, and lead on the Ketamine for reduction of Alcoholic Relapse (KARE) clinical trial, which is considered a medical benchmark.
Chair: George Scorsis
George has 15 years’ experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks and, most recently, medical cannabis.
?


Formerly President of Red Bull Canada, he was instrumental in restructuring the organisation and growing the business to $150 MM in revenue.
CEO: Anthony Tennyson, BA, MSc, MBA
Anthony is an experienced financial services industry executive with 10 years in international strategy, commercial leadership roles with Aon plc, and 5 years with Merrill Lynch and Bank of Ireland. Anthony holds an MBA in Strategy and Finance and an MSc in Technology both from UCD, Ireland’s top ranked business school.
CFO: Jonathan Held, CPA CA
Jonathan is a chartered professional accountant, with CFO level experience for private / public companies. Jonathan has worked in a number of sectors including technology, biotech and natural resources, both domestic and international, and has been involved in numerous successful public market transactions including Initial Public Offerings, Reverse Takeovers and financings.

COO: James Collins BSc, MPhil in Psychology
James is a senior business leader and mental health champion with 17 years of experience with Accenture Strategy, 7 years as MD, designing and delivering corporate, digital and operating model strategies. James holds a BSc and MPhil in Psychology from University College London (UCL)

Nice read thanks for sharing! I took a hard look at the quarterly report. Some really good info there.

Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022

$AWKN $AWKNF

Good morning $AWKN $AWKNF

Awakn Is Hopeful For Addiction Treatment Milestones in 2022

https://www.greenmarketreport.com/awakn-is-hopeful-for-addiction-treatment-milestones-in-2022/

Good Morning $AWKNF $AWKN

What a turd this is.

Sinking like a rock, that chart is awful.

Very nice financials for a company in an industry that's just beginning!

.@awakn_ls is a well-positioned #psychedelics:
- Phase 3, is expected to begin in 2nd half of 2022
- Applied for several grants, one of which, if successful, would cover a substantial amount of Phase 3 trial

$AWKN $AWKNF
https://t.co/0bgnVpBoP9
(Sponsored Content) https://t.co/4u0oucojci

Great loading past couple days!

$AWKN $AWKNF

NEO: $AWKN flying $AWKNF

Follow $AWKNF on Twitter ---> https://twitter.com/awakn_ls

"Today's results demonstrate the significant momentum building in our business across both our research and development pipeline and in our therapeutics commercialization business. The addiction treatment market opportunity is, unfortunately, large and growing, and Awakn is uniquely positioned to offer proven therapeutics supported by data to sufferers for whom the current standard of care is inadequate and relapse rates are unacceptably high.

Toronto, Ontario--(Newsfile Corp. - June 14, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended April 30, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars ("CAD"), unless otherwise specified.

Anthony Tennyson, Chief Executive Officer of Awakn Life Sciences, stated, "Today's results demonstrate the significant momentum building in our business across both our research and development pipeline and in our therapeutics commercialization business. The addiction treatment market opportunity is, unfortunately, large and growing, and Awakn is uniquely positioned to offer proven therapeutics supported by data to sufferers for whom the current standard of care is inadequate and relapse rates are unacceptably high.

Morning! Major markets looking good this morning. Let's see this turnaround $AWKNF

Good Morning $AWKNF

Investor Enquiries:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony@awaknlifesciences.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Nora Popova
Awakn@roadcommunications.co.uk
$AWKNF

I love the direction they are going !

Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions. Promising Results Merit Larger Study Which Awakn is Initiating. $AWKNF

A core part of Awakn's efforts is to continually strengthen their IP portfolio as they work to bring effective therapies to chronic addiction sufferers in desperate need. $AWKNF

With no effective pharmacological treatments available globally at present for behavioral addictions, the study results and the patent filing position Awakn at the forefront of the industry at a time when rates of behavioral addictions are increasing at an alarming pace and sufferers have few treatment options which deliver poor outcomes.$AWKNF

Addiction is one of the biggest unmet medical needs of our time, affecting over 20% of the global population and is an industry valued at over $100bn per annum. Awakn is disrupting this underperforming industry by rapidly advancing the next generation of drugs and therapies to be used in combination, through preclinical research and clinical stage trials.$AWKNF

Awakn Life Science's team consists of renowned research experts, world leading chemists, scientists, psychiatrists, and psychologists.$AWKNF

In just two years, the AWKNF team has built a clinical stage company with a promising pipeline and an established presence in the UK. and Dennis Purcell looks forward to helping them establish a similar presence and profile in the US as they continue to grow and scale.$AWKNF

AwKNF CEO, Anthony Tennyson said to have someone of Dennis' experience, quality and calibre is excellent for their company, but also a sign of where they are heading. Dennis has also worked with so many of the top-biotech companies globally and his input and counsel will have a very positive impact as Awaken Life Sciences Corp. continues to grow their business. $AWKNF

They are doing great work! $AWKNF

Awaken Life Sciences Corp. announced that Dennis Purcell has joined AWKNF as a Special Advisor to the CEO Mr. Purcell brings a wealth of life science and investment experience . Mr. Purcell is the Founder of Aisling Capital LLC, a major life sciences venture capital firm based in New York City and has previously served as the Fund's Senior Managing Partner and Advisor. $AWKNF

Great info! $AWKNF

The addiction treatment market opportunity is, unfortunately, large and growing, and AWKNF is uniquely positioned to offer proven therapeutics supported by data to sufferers for whom the current standard of care is inadequate and relapse rates are unacceptably high.$AWKNF

Awaken Life Sciences Corp. announced its financial results and business highlights for the three months ended April 30, 2022. During the quarter awknf said they achieved a number of significant milestones, including the completion of the world's first Ketamine study for a range of behavioural addictions including Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder and Compulsive Sexual Behavior Disorder. $AWKNF

Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
Press Release | 06/02/2022
Toronto, Ontario--(Newsfile Corp. - June 2, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder. Awakn announced on May 19, 2022, that the Company had completed a successful pilot study for a range of behavioral addictions. On May 26, 2022, Awakn announced the filing of a Patent Cooperation Treaty (PCT) for the treatment of behavioral addictions with ketamine and ketamine-assisted psychotherapy.

The larger study announced today will include 42 patients who are suffering from Gambling Disorder and will see participants undergo a memory reactivation procedure, which is designed to weaken the link between reward and addiction memories. The larger placebo-controlled study will be the first investigation globally to explore this technique to treat Gambling Disorder.

The study will use advanced brain imaging technology EEG (Electro Encephalography) and will index the synaptic plasticity post-ketamine administration with the aim of identifying the window of greatest neuroplastic change. This would potentially allow Awakn to predict when therapy will be at its most effective due to the neuroplasticity. The study will also collect detailed pharmacokinetic (PK) data and analyze metabolites as well as examining neurological biomarkers.

Awakn CEO Anthony Tennyson commented, "Awakn is dedicated to helping people who are suffering from addiction, and we are greatly enthused by the significant research & development milestones we have passed in recent weeks. None of this would be possible without the dedication of the Awakn team and I would like to formally thank them, and everyone involved, including patients, physicians, and carers."

Gambling Disorder affects up to 450 million[1] people globally. In the US alone, it is estimated that more than 2.5% of the population suffer from Gambling Disorder, that is over 8 million people2. With no pharmacological treatments currently available, the need to find an effective treatment has never been more acute.

AWKNF) is a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder $AWKNF

Mr. Purcell currently serves on the Board of Directors of Real Endpoints, Ichnos Pharmaceuticals, Summus Global, Shorla Oncology, and Embera Pharma. He is also an advisor to Better Health, Cellevolve and xCellerate. He has previously served on the Boards of many other public and private Life Sciences companies. In addition, Mr. Purcell serves as an Executive-in-Residence at Columbia University and as an Endowment Committee member at the University of Delaware, where he also serves on the Pharmaceutical Innovation Board.

Good to see you! $AWKNF

looks good $AWKNF

$AWKNF Biotech Disruptor - Awakn Life Sciences CEO Interview

$AWKNF Ramping up!! Hmmmm

$AWKNF Video ~ CEO Anthony Tennyson: Developing and Delivering the Next Generation of Addiction Treatments

Outstanding Shares ~ 26,918,557 ~ 06/13/2022
Restricted ~ 19,085,304 ~ 06/13/2022
Unrestricted ~ 7,833,253 ~06/13/2022

Good to see you $AWKNF

Awesome track record for Dennis

$AWKNF

Good Morning!

$AWKNF